drugset / Trial / NCT00671502

A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back

NCT00671502

Phase 3 Completed 840 enrolled Meda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if two sustained released formulations of carisoprodol are more effective than placebo.

Timeline

Start
2008-04
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Carisoprodol Small molecule 500 mg
Subject Carisoprodol Small molecule 700 mg

Indications

No indication recorded.